Recent News
Lung Cancer Awareness Month Starts Today
Today starts Lung Cancer Awareness Month. In November, we come together to recognize this deadly cancer and learn about different causes and treatments. Knowing the different statistics and causes could…
Mesothelioma Early Detection by VOCs (MED-VOC)
This is a two phase study, The first phase (phase 1) will identify potential biomarkers among asbestos exposed individuals with pleural mesothelioma. The second phase (phase 2), is a double blinded case-matched controlled study to determine the predictive capability, sensitivity, and specificity of these biomarkers in detecting early stage pleural mesothelioma. Biomarkers in the form of volatile organic compounds (VOC) in exhaled breath samples from subjects with either pleural mesothelioma or pleural plaques, will be evaluated. A biomarker present in serum will also be concurrently evaluated in the same cohort. The soluble serum biomarker mesothelin related peptides (SMRP), which has been posited as a biomarker for mesothelioma, will be analyzed for its relationship to the breath VOC profile.
First FDA Approved Mesothelioma Treatment in 15 Years to be Used Soon
A new cancer treatment using electricity has been approved for use in mesothelioma patients. The NovoTTF-100L uses Tumor Treating Fields, which are electric signals tuned to a specific frequency, to…
Phase I Trial HIPEC With Nal-irinotecan
The purpose of this study is to assess the effectiveness and safety of intraperitoneal administration of heated nanoliposomal Irinotecan in cytoreductive surgery (CRS), which is surgery designed to remove as much of the cancer as possible, and heated intraperitoneal chemotherapy (HIPEC) procedures.
Looking Back on Mesothelioma Awareness Day
Mesothelioma is a very rare and preventable cancer and because of this, many people do not know it exists or what causes it. Mesothelioma Awareness Day helps solve this by…
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection (SMARTER)
Primary Outcome Measures Maximum Tolerated Dose for Background Radiation [ Time Frame: Up to five years ]AEs will be graded by CTCAE. Maximum tolerated dose is the dose level that do not result in…
CAR T-Cell Therapy Could Soon be used on Mesothelioma Patients
An immunotherapy treatment that utilizes T cells to fight cancer may soon be covered by Medicare for mesothelioma patients. Immunotherapy is still an emerging set of cancer treatments that utilizes…
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.
MicroRNA Could be used to Quickly Diagnose Mesothelioma
Biomarkers are measureable substances that indicate if someone has a disease. Doctors and researchers are able to find different substances within a person’s body and deduce that the person has…
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Treatment outcomes for people with pleural or peritoneal mesothelioma are often poor. The drug LMB-100 can attack and kill cancer cells. The drug pembrolizumab helps the immune system fight cancer. Together, these drugs might help people with these cancers.
